GnRH agonist
Triptorelin
Answer
Triptorelin is authorised or registered in the US, the EU, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 10 of the 10 registers read. Highest trial phase: Phase 4 (after approval). It has 317 registered trials, 71 of them running. Brand names on the FDA label register: Trelstar and Triptodur.
RegulatorTrial register10 regulators' registers, read 2026-08-31 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
317 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 32 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 158 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-08-31 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
CHANGE ALERTS
Get an email when this changes
One email when the status of Triptorelin changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 317 trials
| 2022-501024-20-00 | CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9 no status recorded · register updated 2026-09-29 |
|---|---|
| 2024-519655-28-00 | OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women no status recorded · register updated 2026-09-14 |
| NCT07816562 | Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST) currently recruiting participants · register updated 2026-09-11 |
| 2023-509494-23-00 | DARIUS : A RANDOMIZED NON-COMPARATIVE PHASE II MULTICENTRIC TRIAL ON SHORT TERM DAROLUTAMIDE (ODM-201) CONCOMITANT TO RADIATION TH no status recorded · register updated 2026-09-07 |
| NCT06763926 | Intranasal Nafarelin For Triggering Oocyte Maturation not yet recruiting participants · register updated 2026-09-03 |
| NCT02005887 | TRial on the Endocrine Activity of Neoadjuvant Degarelix completed · register updated 2026-09-02 |
| NCT06513962 | Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer currently recruiting participants · register updated 2026-08-31 |
| NCT04557059 | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer running, but no longer enrolling · register updated 2026-08-28 |
| NCT00066690 | Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women completed · register updated 2026-08-26 |
| NCT07782840 | QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemother not yet recruiting participants · register updated 2026-08-26 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.